Asset
Hyaluronidase (Human Recombinant)
Halozyme Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00311519 | phase4 | completed | 2005-11-01 | — | Halozyme Therapeutics | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects |
| NCT00435604 | phase1 | completed | 2007-02-01 | — | Halozyme Therapeutics | A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase |
| NCT00803972 | phase1 | completed | 2008-11-01 | 2009-08-28 | Halozyme Therapeutics | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 |
| NCT00593281 | phase3 | completed | 2006-01-01 | 2006-10-01 | Halozyme Therapeutics | INFUSE Morphine Study |
| NCT00862849 | phase1 | completed | 2009-03-01 | 2009-06-01 | Halozyme Therapeutics | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 021859 | BLA | Halozyme Therapeutics, Inc. |
Marketed products (1)
- HYLENEX RECOMBINANT